Glycated Hemoglobin as a First-line Screening Test for Cystic Fibrosis‒Related Diabetes and Impaired Glucose Tolerance in Children With Cystic Fibrosis: A Validation Study
Autor: | Cécile Q.T. Nguyen, Quitterie Reynaud, Katherine Desjardins, Rémi Rabasa-Lhoret, Azadeh Shohoudi, Geneviève Mailhot, Valérie Boudreau, Florence Racine, Marie-Hélène Denis |
---|---|
Rok vydání: | 2020 |
Předmět: |
Blood Glucose
Pediatrics medicine.medical_specialty endocrine system diseases Screening test Cystic Fibrosis Endocrinology Diabetes and Metabolism First line Cystic fibrosis-related diabetes Population 030209 endocrinology & metabolism Cystic fibrosis Impaired glucose tolerance 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Endocrinology Diabetes mellitus Glucose Intolerance Internal Medicine Diabetes Mellitus Medicine Humans 030212 general & internal medicine education Child Glycated Hemoglobin education.field_of_study business.industry nutritional and metabolic diseases General Medicine medicine.disease chemistry Glycated hemoglobin business |
Zdroj: | Canadian journal of diabetes. 45(8) |
ISSN: | 2352-3840 |
Popis: | Objectives Our aims in this study were to document the screening rate for cystic fibrosis‒related diabetes (CFRD) in children followed at a cystic fibrosis (CF) clinic in Canada and to evaluate the accuracy of various glycated hemoglobin (A1C) cutoffs to screen for CFRD and impaired glucose tolerance (IGT) in a pediatric CF population. Methods The CFRD screening rate was calculated over a follow-up period of up to 8 years among children who attended the CF clinic between 1993 and 2018. Test performance of A1C at various thresholds ranging from 5.5% to 6.2% was compared with the oral glucose tolerance test (OGTT) as the reference method. Children with CF aged ≥10 years with an OGTT performed within 120 days of A1C measurement were included in the analysis. Results The overall CFRD screening rate was 53.0%. A total of 256 children were included for the A1C performance analysis, of whom 8.6% had an OGTT-confirmed CFRD diagnosis. An A1C threshold of 5.8% demonstrated an optimal balance between sensitivity (90.9%) and specificity (60.7%) for CFRD screening, leading to a potential reduction of 56.3% of the annual required OGTTs. A1C demonstrated poor accuracy for identifying children with IGT. Conclusions An A1C threshold ≥5.8% allows for identification of children requiring further CFRD investigations, which may reduce the clinical burden of children with CF without compromising the ability of early CFRD diagnosis. |
Databáze: | OpenAIRE |
Externí odkaz: |